Repligen (RGEN)
(Delayed Data from NSDQ)
$146.95 USD
+4.81 (3.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $146.98 +0.03 (0.02%) 5:06 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.95 USD
+4.81 (3.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $146.98 +0.03 (0.02%) 5:06 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Repligen (RGEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
by Zacks Equity Research
Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
by Zacks Equity Research
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ¿¿-thalassemia.
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
by Zacks Equity Research
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.
aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923
by Zacks Equity Research
aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.
BOLT Enters Into a Collaboration Agreement With Bristol Myers
by Zacks Equity Research
BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
by Zacks Equity Research
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree
by Zacks Equity Research
The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Roche (RHHBY) Withdraws Tecentriq for Breast Cancer in the U.S.
by Zacks Equity Research
Roche (RHHBY) will withdraw Tecentriq for treating adults with unresectable locally advanced or metastatic triple-negative breast cancer in the United States.
BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.
Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug
by Zacks Equity Research
Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.
Repligen (RGEN) Up 16.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug
by Zacks Equity Research
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
by Zacks Equity Research
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS
by Zacks Equity Research
AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.
Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review
by Zacks Equity Research
Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
J&J (JNJ) CEO Alex Gorsky to Resign, Joaquin Duato to Succeed
by Zacks Equity Research
J&J's (JNJ) CEO Alex Gorsky who has led the company for almost a decade resigns. Joaquin Duato to succeed as CEO.
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study
by Zacks Equity Research
Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.